Research summary ·
Prognostic value of lymphocyte to monocyte ratio for metastatic renal cell carcinoma: a systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 8 Nov 2026.
What was studied
This review asked whether a blood marker predicts outcome in advanced kidney cancer. The marker is the lymphocyte to monocyte ratio, or LMR. The team searched 4 databases up to November 2025. They pooled 11 studies with 1763 people. The studies were observational. Quality was judged with a standard scale.
What they found
A lower LMR was linked to shorter overall survival. It was also linked to a shorter time before the cancer progressed. Overall survival results varied a lot between studies. Progression results varied little. A test pointed to publication bias in overall survival. The link stayed after the authors corrected for it.
What it means for patients
The authors say a low LMR points to a poor outlook. They call LMR a cheap, easy marker. They say it can help sort risk and guide care. They add that its cut-off values and role need more checks in future studies.
Why it is not certain yet
The studies were observational, so the link is not proof of cause. Overall survival results varied a lot. Publication bias was found for that outcome. The authors say cut-off values and its role need testing in prospective studies.
Source
Prognostic value of lymphocyte to monocyte ratio for metastatic renal cell carcinoma: a systematic review and meta-analysis.
PubMed · PMID 42983359We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Kidney cancer publications